For over two decades Pattern Pharma’s founders and its scientific team have worked to unlock the power of the innate immune system, which efforts have culminated in Pattern’s P2PAR-100 product which represents a differentiated approach to fighting cancer and infectious disease. While the immune system is our most powerful tool for maintaining good health, the flip side is that immune failure (dysregulation) underlies many cancers and infectious diseases. The immune system’s two key pillars are innate immunity and adaptive immunity, with the innate immune system being the first to respond to pathogens and other threats (e.g., damaged cells which have the potential to develop into full-blown tumors) which are sensed through hard-wired receptors, i.e. pattern recognition receptors such as Toll-like receptors (TLRs). Pattern’s lead product candidate, P2PAR-100, is a TLR agonist (i.e., a substance which binds to the TLR) that activates the innate immune system safely and effectively. In more detail, P2PAR-100 binds to TLR4, as well as to TLR1/2 and TLR2/6, and it activates key innate immune cells including macrophages, dendritic cells (DCs) and natural killer (NK) cells. Pattern has close collaborations with leading institutions including the M.D. Anderson Cancer Clinic (Houston), Massachusetts General Hospital and Harvard University (Boston), McGill University (Montreal) and the University of Toronto, the National Research Council of Canada (Ottawa and Montreal).